Are the leukocyte telomere length attrition and telomerase activity alteration potential predictor biomarkers for sporadic TAA in aged individuals?

Age

Volumn 36, Issue 5, 2014, Pages

  Balistreri, Carmela R ^a   Pisano, Calogera ^a   Martorana, Adriana ^a   Triolo, Oreste F ^a   Lio, Domenico ^a   Candore, Giuseppina ^a   Ruvolo, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Biological ageing; Leukocyte telomere length attrition; Predictor TAA biomarkers; Sporadic TAA; Telomere activity alteration

Indexed keywords

BIOLOGICAL MARKER; DNA;

AGING; DNA REPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; RISK FACTOR; TELOMERE; TELOMERE SHORTENING; THORACIC AORTA ANEURYSM; TUNEL ASSAY;

AGING; AORTIC ANEURYSM, THORACIC; BIOLOGICAL MARKERS; DNA; DNA REPLICATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LEUKOCYTES; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; RISK FACTORS; TELOMERE; TELOMERE SHORTENING;

EID: 84924342441     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-014-9700-x     Document Type: Article

References (58)

1. Atturu G, Brouilette S, Samani N, London N, Sayers R, Bown M (2010) Short leukocyte telomere length is associated with abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 39(5):559–564. doi:10.1016/j.ejvs.2010.01.013
2. Bachschmid M, Schildknecht S, Matsui R, Zee R, Haeussler D, Cohen R, Pimental D, Bv L (2013) Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease. Ann Med 45(1):17–36. doi:10.3109/07853890.2011.645498
3. Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E, Franceschi C, Caruso C (2004) Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 292(19):2339–2340. doi:10.1001/jama.292.19.2339
4. Balistreri C, Colonna-Romano G, Lio D, Candore G, Caruso C (2009) TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol 29(4):406–415. doi:10.1007/s10875-009-9297-5
5. Balistreri C, Pisano C, Merlo D, Fattouch K, Caruso M, Incalcaterra E, Colonna-Romano G, Ruvolo G, Candore G (2012) Is the mean blood leukocyte telomere length a predictor for sporadic thoracic aortic aneurysm? Data from a preliminary study. Rejuvenation Res 15(2):170–173. doi:10.1089/rej.2011.1273
6. Balistreri C, Accardi G, Buffa S, Bulati M, Martorana A, Candore G, Colonna-Romano G, Lio D, Caruso C (2013a) Centenarian offspring: a model for understanding longevity. Curr Vasc Pharmacol Dec 18. [Epub ahead of print]
7. Balistreri C, Pisano C, Candore G, Maresi E, Codispoti M, Ruvolo G (2013b) Focus on the unique mechanisms involved in thoracic aortic aneurysm formation in bicuspid aortic valve versus tricuspid aortic valve patients: clinical implications of a pilot study. Eur J Cardiothorac Surg 43(6):e180–e186. doi:10.1093/ejcts/ezs630
8. Balistreri C, Pisano C, D’Amico T, Palmeri C, Candore G, Maresi E, Ruvolo G (2013c) The role of inflammation in type A aortic dissection: data of a pilot study. Eur J Inflammation 11:269–278
9. Balistreri C, Candore G, Accardi G, Colonna-Romano G, Lio D (2013d) NF-κB pathway activators as potential ageing biomarkers: targets for new therapeutic strategies. Immun Ageing 10(1):24. doi:10.1186/1742-4933-10-24
10. Balistreri C, Maresi E, Pisano C, di Maggio F, Vaccarino L, Caruso C, Lio D, Ruvolo G, Candore G (2014a) Identification of three particular morphological phenotypes in sporadic thoracic aortic aneurysm (S-TAA): the phenotype III as S-TAA biomarker in aged individuals. Rejuvenation Res 17(2):192–196. doi:10.1089/rej.2013.1505
11. Balistreri CR, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, Genovese S, Franceschi C, SpazzafumoL FP, Candore G, Caruso C, Lio D, Testa R (2014b) Evidences of +896 A/G TLR4 polymorphism as an indicative of prevalence of complications in T2DM patients. Mediat Inflamm 2014:973139. doi:10.1155/2014/973139
12. Bhupatiraju C, Saini D, Patkar S, Deepak P, Das B, Padma T (2012) Association of shorter telomere length with essential hypertension in Indian population. Am J Hum Biol 24(4):573–578. doi:10.1002/ajhb.22264
13. Björck M, Ravn H, Nilsson T, Wanhainen A, Nilsson P (2011) Blood cell telomere length among patients with an isolated popliteal artery aneurysm and those with multiple aneurysm disease. Atherosclerosis 219(2):946–950. doi:10.1016/j.atherosclerosis.2011.09.034
14. Blackburn EH (2010) Telomeres and telomerase: the means to the end (Nobel lecture). Angew Chem Int Ed Engl 49(41):7405–7421. doi:10.1002/anie.201002387
15. Centers for Disease Control and Prevention; National Center for Injury Prevention Control. Available at: http://webappa.cdc.gov/cgi-bin/broker.exe. Accessed January, 2014
16. De Meyer T, Rietzschel E, De Buyzere M, Van Criekinge W, Bekaert S (2011) Telomere length and cardiovascular aging: the means to the ends? Ageing Res Rev 10(2):297–303. doi:10.1016/j.arr.2010.11.001
17. Dimitroulis D, Katsargyris A, Klonaris C, Avgerinos E, Fragou-Plemenou M, Kouraklis G, Liapis CD (2011) Telomerase expression on aortic wall endothelial cells is attenuated in abdominal aortic aneurysms compared to healthy nonaneurysmal aortas. J Vasc Surg 54(6):1778–1783. doi:10.1016/j.jvs.2011.06.079
18. Eissler R, Schmaderer C, Rusai K, Kühne L, Sollinger D, Lahmer T, Witzke O, Lutz J, Heemann U, Baumann M (2011) Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res 34(5):551–558. doi:10.1038/hr.2010.270
19. Elefteriades J, Farkas E (2010) Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 55(9):841–857. doi:10.1016/j.jacc.2009.08.084
20. El-Hamamsy I, Yacoub M (2009) Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol 6(12):771–786. doi:10.1038/nrcardio.2009.191
21. Epel E, Merkin S, Cawthon R, Blackburn E, Adler N, Pletcher M, Seeman T (2008) The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. Aging (Albany NY) 1(1):81–88
22. Findeisen H, Gizard F, Zhao Y, Cohn D, Heywood E, Jones K, Lovett D, Howatt D, Daugherty A, Bruemmer D (2011) Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 31(2):253–260. doi:10.1161/ATVBAHA.110.218545
23. Fitzpatrick A, Kronmal R, Kimura M, Gardner J, Psaty B, Jenny N, Tracy R, Hardikar S, Aviv A (2011) Leukocyte telomere length and mortality in the cardiovascular health study. J Gerontol A Biol Sci Med Sci 66(4):421–429. doi:10.1093/gerona/glq224
24. Frantz S, Ertl G, Bauersachs J (2007) Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc 4(8):444–454. doi:10.1038/ncpcardio0938
25. Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, Pawelec G (2010) Aging, frailty and age-related diseases. Biogerontology 11(5):547–563. doi:10.1007/s10522-010-9287-2
26. Fyhrquist F, Silventoinen K, Saijonmaa O, Kontula K, Devereux RB, de Faire U, Os I, Dahlöf B (2011) Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens 25(12):711–718. doi:10.1038/jhh.2011.57
27. Fyhrquist F, Saijonmaa O, Strandberg T (2013) The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol 10(5):274–283
28. Goldschmidt-Clermont P, Dong C, Seo D, Velazquez O (2012) Atherosclerosis, inflammation, genetics, and stem cells: 2012 update. CurrAtheroscler Rep 14(3):201–210. doi:10.1007/s11883-012-0244-1
29. González-Ramos M, Calleros L, López-Ongil S, Raoch V, Griera M, Rodríguez-Puyol M, de Frutos S, Rodríguez-Puyol D (2013) HSP70 increases extracellular matrix production by human vascular smooth muscle through TGF-β1 up-regulation. Int J Biochem Cell Biol 45(2):232–242. doi:10.1016/j.biocel.2012.10.001
30. Hofmann U, Ertl G, Frantz S (2011) Toll-like receptors as potential therapeutic targets in cardiac dysfunction. Expert Opin Ther Targets 15(6):753–765. doi:10.1517/14728222.2011.566560
31. Huusko T, Santaniemi M, Kakko S, Taskinen P, Ukkola O, Kesäniemi Y, Savolainen M, Salonurmi T (2012) Long telomeres in blood leukocytes are associated with a high risk of ascending aortic aneurysm. PLoS One 7(11):e50828. doi:10.1371/journal.pone.0050828
32. Huzen J, de Boer R, van Veldhuisen D, van Gilst W, van der Harst P (2010) The emerging role of telomere biology in cardiovascular disease. Front Biosci (Landmark Ed) 15:35–45
33. Huzen J, Wong L, van Veldhuisen D, Samani N, Zwinderman A, Codd V, Cawthon R, Benus G, van der Horst I, Navis G, Bakker S, Gansevoort R, de Jong P, Hillege H, van Gilst W, de Boer R, van der Harst P (2014) Telomere length loss due to smoking and metabolic traits. J Intern Med 275(2):155–163. doi:10.1111/joim.12149
34. Incalcaterra E, Accardi G, Balistreri C, Caimi G, Candore G, Caruso M, Caruso C (2013) Pro-inflammatory genetic markers of atherosclerosis. Curr Atheroscler Rep 15(6):329. doi:10.1007/s11883-013-0329-5
35. Ince H, Nienaber C (2007) Etiology, pathogenesis and management of thoracic aortic aneurysm. Nat Clin Pract Cardiovasc Med 4(8):418–427. doi:10.1038/ncpcardio0937
36. Ionita MG, Arslan F, de Kleijn DP, Pasterkamp G (2010) Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. J Innate Immun 2(4):307–315. doi:10.1159/000314270
37. Kim N, Wu F (1997) Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 25(13):2595–2597
38. Kuivaniemi H, Platsoucas CD, Tilson MD 3rd (2008) Aortic aneurysms: an immune disease with a strong genetic component. Circulation 117(2):242–252. doi:10.1161/CIRCULATIONAHA.107.690982
39. Laurent S (2012) Defining vascular aging and cardiovascular risk. J Hypertens 30(Suppl):S3–S8. doi:10.1097/HJH.0b013e328353e501
40. Li H, Xu H, Liu S (2011) Toll-like receptors 4 induces expression of matrix metalloproteinase-9 in human aortic smooth muscle cells. Mol Biol Rep 38(2):1419–1423. doi:10.1007/s11033-010-0246-4
41. Mainous A, Diaz V (2010) Telomere length as a risk marker for cardiovascular disease: the next big thing? Expert Rev Mol Diagn 10(8):969–971. doi:10.1586/erm.10.69
42. Minamino T, Komuro I (2008) Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. Nat Clin Pract Cardiovasc Med 5(10):637–648. doi:10.1038/ncpcardio1324
43. Navi A, Patel H, Shaw S, Baker D, Tsui J (2013) Therapeutic role of toll-like receptor modification in cardiovascular dysfunction. Vasc Pharmacol 58(3):231–239. doi:10.1016/j.vph.2012.10.001
44. Nilsson P (2012) Impact of vascular aging on cardiovascular disease: the role of telomere biology. J Hypertens 30(Suppl):S9–S12. doi:10.1097/HJH.0b013e328353e512
45. O’Rourke M, Adji A, Namasivayam M, Mok J (2011) Arterial aging: a review of the pathophysiology and potential for pharmacological intervention. Drugs Aging 28(10):779–795. doi:10.2165/11592730-000000000-00000
46. Ouzounian M, Lee D, Gramolini A, Emili A, Fukuoka M, Liu P (2007) Predict, prevent and personalize: genomic and proteomic approaches to cardiovascular medicine. Can J Cardiol 23 (Suppl A):28A–33A. doi:10.1016/S0828-282X(07)71003-6
47. Phan H, Alpert J, Fain M (2008) Frailty, inflammation, and cardiovascular disease: evidence of a connection. Am J Geriatr Cardiol 17(2):101–107, Review. PubMed PMID: 1832695
48. Pisano C, Maresi E, Balistreri C, Candore G, Merlo D, Fattouch K, Bianco G, Ruvolo G (2012a) Histological and genetic studies in patients with bicuspid aortic valve and ascending aorta complications. Interact Cardiovasc Thorac Surg 14(3):300–306. doi:10.1093/icvts/ivr114
49. Pisano C, Maresi E, Merlo D, Balistreri C, Candore G, Caruso M, Codispoti M, Ruvolo G (2012b) A particular phenotype of ascending aorta aneurysms as precursor of type A aortic dissection. Interact Cardiovasc Thorac Surg 15(5):840–846. doi:10.1093/icvts/ivs347
50. Pryshchep O, Ma-Krupa W, Younge B, Goronzy J, Weyand CM (2008) Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118(12):1276–1284. doi:10.1161/CIRCULATIONAHA.108.789172
51. Ruvolo G, Pisano C, Maresi E, Candore G, Palmeri C, Lio D, Balistreri C (2014) Can the TLR-4 mediated signaling pathway be considered “a key inflammatory promoter of sporadic TAA”?. Mediators Inflamm, volume 2014, Article ID 349476, 14 pages http://dx.doi.org/10.1155/2014/349476
52. Saliques S, Zeller M, Lorin J, Lorgis L, Teyssier JR, Cottin Y, Rochette L, Vergely C (2010) Telomere length and cardiovascular disease. Arch Cardiovasc Dis 103(8–9):454–459. doi:10.1016/j.acvd.2010.08.002
53. Sikora E, Bielak-Zmijewska A, Mosieniak G (2013)Cellular senescence in ageing, age-related disease and longevity. CurrVascPharmacol Dec18. [Epubahead of print]
54. Song Y, Shen H, Schenten D, Shan P, Lee P, Goldstein D (2012) Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 32(1):103–109. doi:10.1161/ATVBAHA.111.236349
55. Wadley A, van Veldhuijzen Zanten J, Aldred S (2013) The interactions of oxidative stress and inflammation with vascular dysfunction in ageing: the vascular health triad. Age (Dordr) 35(3):705–718. doi:10.1007/s11357-012-9402-1
56. Wilson W, Herbert K, Mistry Y, Stevens S, Patel H, Hastings R, Thompson M, Williams B (2008) Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J 29(21):2689–2694. doi:10.1093/eurheartj/ehn386
57. Yan J, Yang Y, Chen C, Peng J, Ding H, Wen Wang D (2011) Short leukocyte telomere length is associated with aortic dissection. Intern Med 50(23):2871–2875. doi:10.2169/internalmedicine.50.5958
58. Yang Z, Huang X, Jiang H, Zhang Y, Liu H, Qin C, Eisner G, Jose PA, Rudolph L, Ju Z (2009) Short telomeres and prognosis of hypertension in a Chinese population. Hypertension 53(4):639–645. doi:10.1161/HYPERTENSIONAHA.108.123752